Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

NCT00179725 | Terminated Phase 1

• 1 other identifier: CC-5013-OVRY-001
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 5

Brief Summary

Phase I will determine the MTD and evaluated the safety profile of oral lenalidomide on days 1-21 when given with liposomal doxorubicin on day 1 of every 28 day cycle Phase II will commence once the MTD is established, additional subjects will be enrolled and receive oral lenalidomide on days 1-21 with liposomal doxorubicinon day 1 in 28 day cycles until disease progression is documented.

Conditions

Ovarian Cancer

Keywords

cc-5013; revlimid; ovarian cancer; celgene

Outcome Measures

Primary Outcomes (2)

• Phase I-To determine the maximum tolerated dose (MTD) and evaluate the safety profile of oral lenalidomide on days 1 - 21 and liposomal doxorubicin on day 1 every 28 days, as combination therapy to subjects with advanced ovarian or primary peritoneal ca

• Phase II-To explore the anti-tumor activity of the combination of oral lenalidomide on days 1 - 21 and liposomal doxorubicin on day 1 every 28 days when given to subjects with advanced ovarian or primary peritoneal carcinoma.

Secondary Outcomes (2)

• Phase I-To explore the anti-tumor activity of the combination of lenalidomide and liposomal doxorubicin when given to subjects with advanced ovarian or primary peritoneal carcinoma.

• Phase II-To evaluate the safety profile of the combination of lenalidomide and liposomal doxorubicin when given to subjects with advanced ovarian or primary peritoneal carcinoma

Interventions

CC-5013 DRUG

liposomal doxorubicin DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must understand and voluntarily sign an informed consent document.
• Age \> or = to 18 years at the time of signing informed consent form.
• Subjects must be able to adhere to the study visit schedule and other protocol requirements.
• Histological or cytological documentation of advanced ovarian or primary peritoneal carcinoma.
• Radiographic or clinical evidence of measurable metastatic advanced ovarian or primary peritoneal carcinoma. Subjects must have measurable disease at least 2 cm in diameter.
• Subjects must have been treated and progressed following chemotherapy which includes platinum and paclitaxel.
• ECOG performance status of 0 or 1 (Appendix I: ECOG Performance Status Scale).
• Must have 2-d Echocardiogram/MUGA indicating a LVEF above the institutional lower limit of normal within 42 days prior to first dose of study drug.

You may not qualify if:

• Any of the following laboratory abnormalities:
• Absolute neutrophil count (ANC) \<1,500 cells/mm3 (1.5 x 109/L)
• Platelet count \<100,000 cells/mm3 (100 x 109/L)
• Serum creatinine \>2.5 mg/dL (221 mmol/L)
• Serum SGOT/AST or SGPT/ALT \>3.0 x upper limit of normal (ULN)
• Serum total bilirubin \>1.2 mg/dL (20 mmol/L)
• Any serious medical condition or psychiatric illness that places the subject at an unacceptable risk for study participation or would prevent the subject from signing the informed consent.
• Prior history of malignancy (except basal cell or squamous cell carcinoma or carcinoma in situ of the breast) unless the subject has been free of disease for \> or = to 1 years.
• Known brain or leptomeningeal disease (CT scan or MRI of the brain required only in case of clinical suspicion of central nervous system involvement).
• More than 1 prior chemotherapy regimen. However, subjects with platinum sensitive disease (i.e., subjects who fail a platinum containing regimen at least six months after completing the regimen) who are retreated with a platinum containing regimen are eligible.
• Concurrent use of any other anti-cancer agents.
• Any prior use of Lenalidomide.
• Prior \> or = to grade 3 (see Appendix III) allergic reaction/hypersensitivity to thalidomide.
• Prior \> or = grade 3 (see Appendix III) rash or any desquamating (blistering) rash while taking thalidomide.
• Use of any standard or experimental anti-cancer drug therapy within 28 days of the initiation of study drug therapy.

Sponsors & Collaborators

• Celgene Corporation: lead
• Prologue Research International: collaborator

Study Sites (5)

University of California at San Francisco

San Francisco, California, 94115, United States

Location

MD Anderson Cancer Center Orlando

Orlando, Florida, 32806, United States

Location

Memorial Sloan-Kettering Cancer Center

New York, New York, 10021, United States

Location

OU Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States

Location

Swedish Cancer Institute

Seattle, Washington, 98104, United States

Location

MeSH Terms

Conditions

Ovarian Neoplasms

Interventions

Lenalidomide; liposomal doxorubicin

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Intervention Hierarchy (Ancestors)

Phthalimides; Phthalic Acids; Acids, Carbocyclic; Carboxylic Acids; Organic Chemicals; Piperidones; Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Isoindoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: FACTORIAL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: September 10, 2005
• First Posted: September 16, 2005
• Study Start: November 1, 2005
• Study Completion: June 1, 2007
• Last Updated: April 12, 2006

Record last verified: 2006-04

Locations

US (5)